These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 15264108

  • 1. Immunogenicity of interferon beta: differences among products.
    Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P.
    J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
    [Abstract] [Full Text] [Related]

  • 2. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T, Sölberg Sørensen P, Rice G.
    J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
    Prince HE, Lapé-Nixon M, Audette C, Van Horn K.
    J Neuroimmunol; 2007 Oct; 190(1-2):165-9. PubMed ID: 17889376
    [Abstract] [Full Text] [Related]

  • 5. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 6. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European Interferon Beta-1a IM Dose-Comparison Study Investigators.
    Neurology; 2005 Jul 12; 65(1):40-7. PubMed ID: 16009883
    [Abstract] [Full Text] [Related]

  • 7. Neutralizing antibodies to multiple sclerosis treatments.
    Rossman HS.
    J Manag Care Pharm; 2004 Jun 12; 10(3 Suppl B):S12-9. PubMed ID: 15253685
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, Milano E, Melis F, Giordana MT.
    J Neurol Neurosurg Psychiatry; 2002 Aug 12; 73(2):148-53. PubMed ID: 12122172
    [Abstract] [Full Text] [Related]

  • 9. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
    Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A.
    Mult Scler; 2007 Mar 12; 13(2):208-14. PubMed ID: 17439886
    [Abstract] [Full Text] [Related]

  • 10. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P, Calabrese M, Biasi G, Gallo P.
    J Neurol; 2004 Mar 12; 251(3):305-9. PubMed ID: 15015010
    [Abstract] [Full Text] [Related]

  • 11. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP.
    J Interferon Cytokine Res; 2011 Mar 12; 31(3):337-44. PubMed ID: 21226608
    [Abstract] [Full Text] [Related]

  • 12. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ.
    J Neurol Sci; 2008 Sep 15; 272(1-2):8-19. PubMed ID: 18620708
    [Abstract] [Full Text] [Related]

  • 13. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Deisenhammer F, Schellekens H, Bertolotto A.
    J Neurol; 2004 Jun 15; 251 Suppl 2():II31-9. PubMed ID: 15264110
    [Abstract] [Full Text] [Related]

  • 14. Assessment and management of neutralizing antibodies in patients with multiple sclerosis.
    Hartung HP, Munschauer FE.
    J Neurol; 2004 Jun 15; 251 Suppl 2():II40-2. PubMed ID: 15264111
    [Abstract] [Full Text] [Related]

  • 15. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR, Cadavid D, Wolansky L, Skurnick J.
    Neurology; 2009 Nov 03; 73(18):1485-92. PubMed ID: 19884576
    [Abstract] [Full Text] [Related]

  • 16. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM, Rudick RA, Munschauer FE, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K.
    Mult Scler; 2005 Aug 03; 11(4):409-19. PubMed ID: 16042223
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.
    Ross C, Clemmesen KM, Svenson M, Sørensen PS, Koch-Henriksen N, Skovgaard GL, Bendtzen K.
    Ann Neurol; 2000 Nov 03; 48(5):706-12. PubMed ID: 11079533
    [Abstract] [Full Text] [Related]

  • 18. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.
    J Immunol Methods; 2007 Apr 10; 321(1-2):19-31. PubMed ID: 17335844
    [Abstract] [Full Text] [Related]

  • 19. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R.
    Immunopharmacology; 2000 Jul 20; 48(2):95-100. PubMed ID: 10936507
    [Abstract] [Full Text] [Related]

  • 20. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group.
    Neurology; 2005 Jul 12; 65(1):33-9. PubMed ID: 15888603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.